Treviño GG, Hernández BV

Language: Spanish
References: 9
Page: 97-103
PDF size: 502.42 Kb.

Text Extraction

No abstract

REFERENCES

1. Yasunori OIY, Shinohara Y, Kobayashi T. A multicenter prospective randomized trial of corticosteroids In primary therapy for Kawasaki disease: clinical course and Coronary artery outcome. J Pediatr 2006; 149: 336-41.

2. Burns J, Glodé M. Kawasaki syndrome. Lancet 2004; 364: 533-544.

3. Sinha B, Balakumar T. BCG reactivation: A useful diagnostic tool even for incomplete Kawasaki disease. Arch Dis Child 2005; 90: 891.

4. Esper F, Shapiro E, Weibel C, Ferguson D. Association between a Novel Human Coronavirus and Kawasaki Disease. The Journal of Infectious Diseases 2005; 191: 499–502.

5. Tulloh R, Wood L. Coronary artery changes in patients with Kawasaki disease. Acta Paediatr Suppl 2004: 446.

6. Muta H, Ishii M et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004; 144: 496-9.

7. Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-2771.

8. Lang B. Controversies in the management of Kawasaki disease. Best Prac and Res Clin Rheum 2005; 16(3): 427-433.

9. Burns J, Mason W et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005; 146: 662-7.